Actinium Pharmaceuticals (NYSE:ATNM) Stock Price Down 0.7% – Here’s Why

Actinium Pharmaceuticals, Inc. (NYSE:ATNM)’s stock price dropped 0.7% on Wednesday . The stock traded as low as $1.41 and last traded at $1.42. Approximately 155,911 shares traded hands during trading, a decline of 55% from the average daily volume of 344,008 shares. The stock had previously closed at $1.43.

Actinium Pharmaceuticals Price Performance

The stock’s 50-day simple moving average is $1.44 and its two-hundred day simple moving average is $1.56. The firm has a market capitalization of $44.30 million, a P/E ratio of -1.02 and a beta of -0.37.

Institutional Trading of Actinium Pharmaceuticals

Several institutional investors have recently made changes to their positions in ATNM. North Star Asset Management Inc. raised its stake in Actinium Pharmaceuticals by 100.0% during the 2nd quarter. North Star Asset Management Inc. now owns 20,000 shares of the company’s stock valued at $28,000 after purchasing an additional 10,000 shares during the period. Mayport LLC purchased a new stake in Actinium Pharmaceuticals during the 3rd quarter valued at approximately $35,000. Callan Family Office LLC bought a new stake in shares of Actinium Pharmaceuticals during the first quarter valued at approximately $38,000. Qube Research & Technologies Ltd purchased a new position in shares of Actinium Pharmaceuticals in the second quarter worth $70,000. Finally, AQR Capital Management LLC boosted its position in shares of Actinium Pharmaceuticals by 278.6% during the first quarter. AQR Capital Management LLC now owns 63,249 shares of the company’s stock worth $102,000 after acquiring an additional 46,545 shares during the last quarter. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).